NASDAQ: NMTCNeuroone Medical Technologies Corp Stock
$1.14-0.03 (-2.56%)
Updated Apr 18, 2024
NMTC Price
$1.14
Fair Value Price
-$1.02
Market Cap
$29.56M
52 Week Low
$0.85
52 Week High
$2.00
P/E
-1.68x
P/B
6.69x
P/S
13.47x
PEG
N/A
Dividend Yield
N/A
Revenue
$2.82M
Earnings
-$13.47M
Gross Margin
26.1%
Operating Margin
-478.48%
Profit Margin
-478.5%
Debt to Equity
0.32
Operating Cash Flow
-$13M
Beta
0.58
Next Earnings
May 9, 2024
Ex-Dividend
N/A
Next Dividend
N/A
NMTC Overview
NeuroOne Medical Technologies Corporation is developing thin film electrode technology for continuous electroencephalogram (cEEG) and stereoelectroencephalography (sEEG) recording, spinal cord stimulation, brain stimulation, and ablation solutions for patients suffering from epilepsy, Parkinson's disease, dystonia, essential tremors, chronic pain due to failed back surgeries, and other neurological disorders.NeuroOne Medical Technologies was founded in 2015 and is headquartered in Eden Prairie, MN.
Zen Score
–
Industry Average (27)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how NMTC scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
NMTC ($1.14) is overvalued by 211.31% relative to our estimate of its Fair Value price of -$1.02 based on Discounted Cash Flow (DCF) modelling
Below Fair Value Valuation
NMTC ($1.14) is not significantly undervalued (211.31%) relative to our estimate of its Fair Value price of -$1.02 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
NMTC is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more NMTC due diligence checks available for Premium users.
Be the first to know about important NMTC news, forecast changes, insider trades & much more!
NMTC News
Valuation
NMTC fair value
Fair Value of NMTC stock based on Discounted Cash Flow (DCF)
Price
$1.14
Fair Value
-$1.02
Undervalued by
211.31%
NMTC ($1.14) is overvalued by... subscribe to Premium to read more.
Below Fair Value Valuation
NMTC ($1.14) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
NMTC is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
NMTC price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-1.68x
Industry
28.61x
Market
41.33x
NMTC price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
6.69x
Industry
3.63x
NMTC is poor value based... subscribe to Premium to read more.
P/B vs Industry Valuation
NMTC's financial health
Profit margin
Revenue
$977.6k
Net Income
-$3.3M
Profit Margin
-342.1%
NMTC's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
NMTC's profit margin has decreased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$5.8M
Liabilities
$1.4M
Debt to equity
0.32
NMTC's short-term assets ($5.09M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
NMTC's short-term assets ($5.09M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
NMTC's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
NMTC's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$3.8M
Investing
-$37.1k
Financing
$1.2M
NMTC's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
NMTC vs Medical Device Stocks
Neuroone Medical Technologies Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.